/NUWE
NUWE Stock - Nuwellis, Inc.
Healthcare|Medical - DevicesNASDAQ
$2.16+0.00%
+$0.00 (+0.00%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.38
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NUWE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.14 – $2.18
TARGET (TP)$2.48
STOP LOSS$1.99
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.17
52W High$70.14
52W Low$2.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $8.74M | $8.86M | $8.54M | $7.92M | $7.44M |
| Gross Profit | $5.83M | $4.98M | $4.75M | $4.49M | $4.06M |
| Gross Margin | 66.7% | 56.2% | 55.7% | 56.7% | 54.5% |
| Operating Income | $-10,988,000 | $-17,630,000 | $-17,171,000 | $-19,526,000 | $-17,028,000 |
| Net Income | $-11,165,000 | $-20,209,000 | $-14,525,000 | $-19,554,000 | $-15,836,000 |
| Net Margin | -127.7% | -228.0% | -170.0% | -246.9% | -212.8% |
| EPS | $-8.00 | $-360.07 | $-2921.95 | $-10004.09 | $-20276.57 |
Company Overview
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$17
Average Target
↑ 687.0% Upside
Now
$17
Low
$17
Average
$17
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 29th 2024 | ROTH MKM | Initiation | Buy | $17 |
Earnings History & Surprises
NUWEBeat Rate
11%
Last 18 quarters
Avg Surprise
-2106.1%
EPS vs Estimate
Beats / Misses
2/16
Last 12 quarters
Latest EPS
$0.56
Q4 2025
EPS Surprise History
Q1 24
-5534.5%
$-78.32vs$-1.39
Q2 24
-1879.2%
$-20.98vs$-1.06
Q3 24
-98.6%
$-18.85vs$-9.49
Q4 24
+235.9%
$1.74vs$-1.28
Q1 25
-51.2%
$-0.65vs$-0.43
Q2 25
-53.3%
$-28.99vs$-18.91
Q3 25
-222.7%
$-60.99vs$-18.90
Q4 25
+103.3%
$0.56vs$-17.22
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-17.22 | $0.56 | +103.3% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-18.90 | $-60.99 | -222.7% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-18.91 | $-28.99 | -53.3% | ✗ MISS |
Q1 2025 | Mar 11, 2025 | $-0.43 | $-0.65 | -51.2% | ✗ MISS |
Q4 2024 | Nov 11, 2024 | $-1.28 | $1.74 | +235.9% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-9.49 | $-18.85 | -98.6% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-1.06 | $-20.98 | -1879.2% | ✗ MISS |
Q1 2024 | Mar 5, 2024 | $-1.39 | $-78.32 | -5534.5% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-3.11 | $-63.29 | -1935.0% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-4.02 | $-127.62 | -3074.6% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-3.79 | $-177.97 | -4595.8% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $17.09 | $-174.83 | -1123.0% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-32.00 | $-1293.71 | -3942.8% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-43.00 | $-1433.57 | -3233.9% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-42.00 | $-1468.53 | -3396.5% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-48.00 | $-1433.57 | -2886.6% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-73.00 | $-2622.38 | -3492.3% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-89.00 | $-2517.48 | -2728.6% | ✗ MISS |
Latest News
Nuwellis Presents New Real-World Data Supporting Aquadex Ultrafiltration For Complex AKI Fluid Management At ASN Kidney Week
📈 PositiveBenzinga•Dec 9, 2025, 01:16 PM
Nuwellis Announces A Leading Northeastern U.S. Children's Hospital Has Initiated An Aquadex Ultrafiltration Program
📈 PositiveBenzinga•Dec 4, 2025, 01:16 PM
Nuwellis Q3 EPS $0.56 Beats $(0.41) Estimate, Sales $2.217M Miss $2.500M Estimate
➖ NeutralBenzinga•Nov 12, 2025, 01:18 PM
Nuwellis Receives Notice Of Allowance For New Patent Covering Advanced Safety Mechanisms For Blood Return Line Clamps Used In Extracorporeal Blood Filtration Systems, Including Vivian Pediatric CRRT System
📈 PositiveBenzinga•Nov 10, 2025, 02:09 PM
Robert B. Scott Resigns As CFO Of Nuwellis; John L. Erb Appointed Interim CFO
📉 NegativeBenzinga•Oct 8, 2025, 09:17 PM
Nuwellis Announces Findings From ULTRA-Peds Registry Study Examining Real-World Use Of Aquadex System In Children With AKI, Fluid Overload, Or Congenital Kidney Failure
➖ NeutralBenzinga•Sep 30, 2025, 12:51 PM
Nuwellis Secures U.S. Patent For Hemolysis Sensor Technology In Blood Filtration Systems, Supporting Pediatric Device Vivian And Platform Innovation
📈 PositiveBenzinga•Sep 18, 2025, 01:03 PM
Nuwellis Will Be Issued U.S. Patent Number 12,415,021 Tomorrow Titled "EXTRACORPOREAL BLOOD FILTERING MACHINE AND METHODS (FOR TREATMENT OF FLUID OVERLOAD)".
📈 PositiveBenzinga•Sep 15, 2025, 07:51 PM
NUWE stock has given up its prior gain. Nuwellis shares were trading higher after its development partner, Koronis Biomedical Technologies, was awarded a $3 million NIH grant.
➖ NeutralBenzinga•Sep 9, 2025, 01:36 PM
Nuwellis shares are trading higher after its development partner, Koronis Biomedical Technologies, was awarded a $3 million NIH grant.
📈 PositiveBenzinga•Sep 9, 2025, 01:06 PM
Nuwellis' Development Partner, Koronis Biomedical Technologies Corporation, Awarded $3M NIH Grant To Accelerate Vivian
📈 PositiveBenzinga•Sep 9, 2025, 01:02 PM
Nuwellis' New Dual Lumen Extend Length Catheter Secures FDA 510(k) Clearance
📈 PositiveBenzinga•Aug 21, 2025, 12:16 PM•Also:
Nuwellis signs letter of intent to acquire Rendiatech
📈 PositiveSeeking Alpha•Aug 19, 2025, 12:30 PM
Nuwellis Signs LOI To Acquire Rendiatech, Advancing Renal Monitoring Capabilities Beyond Ultrafiltration; Deal Expected To Close In Q4 2025
📈 PositiveBenzinga•Aug 19, 2025, 12:17 PM
Nuwellis prices public offering of stock and warrants; shares down over 37%
📉 NegativeSeeking Alpha•Jun 9, 2025, 04:09 PM
Frequently Asked Questions about NUWE
What is NUWE's current stock price?
Nuwellis, Inc. (NUWE) is currently trading at $2.16 per share. The stock has moved +0.00% today.
What is the analyst price target for NUWE?
No analyst price targets are currently available for this stock.
What sector is Nuwellis, Inc. in?
Nuwellis, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is NUWE's market cap?
Nuwellis, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does NUWE pay dividends?
No, Nuwellis, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACON
Aclarion, Inc.
$6.20
Mkt Cap: $0.0B
BACK
IMAC Holdings, Inc.
$0.13
Mkt Cap: $0.0B
BCTXW
BriaCell Therapeutics Corp.
$0.04
Mkt Cap: $0.0B
IVF
INVO Fertility, Inc.
$0.33
Mkt Cap: $0.0B
NUVO
Holdco Nuvo Group D.G Ltd. Ordinary Shares
$0.17
Mkt Cap: $0.0B
OCEA
Ocean Biomedical, Inc.
$0.00
Mkt Cap: $0.0B
PETV
PetVivo Holdings, Inc.
$1.16
Mkt Cap: $0.0B
PKBO
Peak Bio, Inc.
$0.02
Mkt Cap: $0.0B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
VINC
Vincerx Pharma, Inc.
$0.01
Mkt Cap: $0.0B
Explore stocks similar to NUWE for comparison